YANA - YOU ARE NOT ALONE NOW
PROSTATE CANCER SUPPORT SITE
SURVIVOR STORIES :
DISCUSSION FORUM :
WIVES & PARTNERS :
TELL YOUR STORY :
UPDATE YOUR STORY :
YANA HOME PAGE :
DON'T PANIC :
GOOD NEWS! :
TREATMENT CHOICES :
ABOUT US :
#5 - GO TO INDEX FOR EARLIER LETTERS
- YOU ARE NOT ALONE NOW
PROSTATE CANCER SUPPORT SITE
|Prostate men need enlightening, not frightening
||December 13, 2011 |
Effects and Zytiga
acetate was approved by the FDA on April 28, 2011 for the treatment of metastatic
prostate cancer. It is now marketed - at least in the US - as Zytiga. Trials are
still being run in other countries - Australia for example, where they are still
There have been some excellent reports of good results, although
not all results were good, and there seems little doubt that Zytiga will become
an important weapon in the arsenal in the fight to manage our shared disease.
is one aspect of Zytiga that everyone should be aware of and that is what is sometimes
termed the "food effect", which in the case of Zytiga is said to be greater than
any other marketed drug.
The package insert (which regrettably is not read
by everyone) states very clearly "No food should be consumed for at least two
hours before the dose of ZYTIGA is taken and for at least one hour after the dose
of ZYTIGA is taken. The tablets should be swallowed whole with water.
Zytiga website goes on to say Taking Zytiga with food may cause more of the
medicine to be absorbed by the body than is needed and this may cause side effects.
how much the dose is increased depends on what is being eaten and when The dose
can increase fivefold with a low-fat meal and tenfold with a high-fat meal. If
a man takes the standard dose – four tablets totalling 1,000 mg daily after
fasting for two hours, then gets hungry and, rather than fast for one more hour,
eats a meal, he could get up to 10 times the intended dose. For this reason it
is probably best to take the dose first thing In the morning and then wait an
hour to eat.
There is an article on this issue at WebMD Food
and Oral Cancer Drugs: A Case of Mislabeling?
Maack and his new site
always ribs me because we are both Platinum Yana Members - more than fifteen years
from diagnosis - he was in fact diagnosed four years before me, almost 20 years
ago. He is also just a bit older than I am, all of which makes him feel that he's
got the edge over me.
Chuck has been on Internet Forums and Mailing Lists
for many years now and his advice is down to earth and simple. Here he is for
example dealing two widely held beliefs - that ADT (Androgen Deprivation Therapy)
has dreadful side effects and always, fails after two years:
personal opinion is that you should get over your concern about androgen deprivation
therapy (ADT). Think about this - and this relates to the physician telling you
that you could get another 15 years - I have been on/off/on/off and only
recently back on androgen deprivation therapy FOR THE PAST 15 YEARS! I still LIVE!
is NOT the horrendous treatment that some claim it to be, and many of those who
claim so never even had the treatment themselves - they rather echo someone else's
comments who may have experienced some of the side effects that can occur, but
that person likely had no idea how he could have relieved whatever side effects
he is complaining about.
Chuck has collected information on all manners
of prostate related issues and has for some time developing digests, which he
terms Observations, on what he feels are the most relevant sources of good information
about these issues. He now has his own website The Prostate Advocate.
I think it is worth
adding Chuck's site to your Bookmarks - plenty of useful reading there.
have always been somewhat concerned about Ultra-Sensitive PSA Tests and even more so by the
so-called "third generation" tests because what is measure by these
is so small that a relatively small error or the "background noise"
generated by other organs can assuredly lead to elevated results which might not
be associated with disease progression.
study published earlier this month highlights. The conclusions of the study
Agreement between prostate specific antigen doubling time calculated
using ultrasensitive vs traditional prostate specific antigen values is poor.
Ultrasensitive prostate specific antigen doubling time is often significantly
more rapid than traditional prostate specific antigen doubling time, potentially
overestimating the risk of clinical recurrence. Until the significance of ultrasensitive
prostate specific antigen doubling time is better characterized, the decision
to proceed with salvage therapy should not be based on prostate specific antigen
doubling time calculated using ultrasensitive prostate specific antigen values.
study is discussed on The "New" Prostate Cancer Infolink
had a very good response to the call for help I made in the last E-Letter to re-develop
parts of the site, particularly the automation of the contributions and updates.
have gone a long way towards identifying aims and achieving them and especial
thanks go to Mark Freedkin
who has already done a great
deal of work. Hopefully, despite the impact of the Holidays, we'll have a system
up for testing before the end of January.
If any of you are due to send
in an update, please just take a few minutes to go to UP DATE YOUR STORY
and send it in. We'd like
the site to be as updated as possible before transferring to the new system.
Links - including a FaceBook one
on Prostate Cancer: The Empowered Patient's Guide
by Stephen Strum MD and
Donna Pogliano has been published in e-book
In my opinion, this book is one of the very best for
those who want to understand the technical aspects of this complex disease of
It is always worth checking on sites like AbeBooks
for cheap second
hand editions of this and other prostate cancer related books.